Angelo Di Leo, Md, Phd
Head of Sandro Pitigliani Medical Oncology Unit
Hospital of Prato, Istituto Toscano Tumori Prato, Italy
Pitigliani Medical Oncology Dept. at the Hospital of Prato, Instituto Toscano.
Norway
Biography
Since 2003, Dr. Di Leo has served as Head of the Sandro Pitigliani Medical Oncology Dept. at the Hospital of Prato, Instituto Toscano. He is a member of the Early Breast Cancer Trialists’ Cooperative Group steering committee and of the Scientific Advisory Council of the Susan G Komen for the Cure®. He also serves as member of the Breast International Group Executive Board. Currently, Dr. Di Leo and colleagues are studying breast cancers that express estrogen receptors (ER) and HER2, referred to as ER-positive and HER2-positive, respectively. These breast cancers are treated with targeted therapies usually in combination with chemotherapy. Since 2003, Dr. Di Leo has served as Head of the Sandro Pitigliani Medical Oncology Dept. at the Hospital of Prato, Instituto Toscano. He is a member of the Early Breast Cancer Trialists’ Cooperative Group steering committee and of the Scientific Advisory Council of the Susan G Komen for the Cure®. He also serves as member of the Breast International Group Executive Board. Currently, Dr. Di Leo and colleagues are studying breast cancers that express estrogen receptors (ER) and HER2, referred to as ER-positive and HER2-positive, respectively. These breast cancers are treated with targeted therapies usually in combination with chemotherapy.
Research Interest
His team will work to identify which patients could safely avoid chemotherapy, and instead receive a CDK4/6 inhibitor with their targeted therapy. CDK4/6 inhibitors are a new class of targeted drugs that have been FDA-approved for patients with advanced ER-positive breast cancer. Dr. Di Leo will use a tumor gene signature called “RBsig" to predict response to CDK4/6 inhibitors. Cancers with low levels of RBsig are less likely to respond to chemotherapy, and may respond better to anti-CDK4/6 therapy.
